New Recombinant Mycobacterium Bovis BCG Expression Vectors: Improving Genetic Control over Mycobacterial Promoters

Overview

Journal Appl Environ Microbiol

Specialties Environmental Health
Microbiology

Date 2016 Feb 7

PMID 26850295

Citations 12

Authors

Alex I Kanno

Cibelly Goulart

Henrique K Rofatto

Sergio C Oliveira

Luciana C C Leite

Johnjoe McFadden

Affiliations

Soon will be listed here.

Abstract

The expression of many antigens, stimulatory molecules, or even metabolic pathways in mycobacteria such as Mycobacterium bovis BCG or M. smegmatis was made possible through the development of shuttle vectors, and several recombinant vaccines have been constructed. However, gene expression in any of these systems relied mostly on the selection of natural promoters expected to provide the required level of expression by trial and error. To establish a systematic selection of promoters with a range of strengths, we generated a library of mutagenized promoters through error-prone PCR of the strong PL5 promoter, originally from mycobacteriophage L5. These promoters were cloned upstream of the enhanced green fluorescent protein reporter gene, and recombinant M. smegmatis bacteria exhibiting a wide range of fluorescence levels were identified. A set of promoters was selected and identified as having high (pJK-F8), intermediate (pJK-B7, pJK-E6, pJK-D6), or low (pJK-C1) promoter strengths in both M. smegmatis and M. bovisBCG. The sequencing of the promoter region demonstrated that it was extensively modified (6 to 11%) in all of the plasmids selected. To test the functionality of the system, two different expression vectors were demonstrated to allow corresponding expression levels of the Schistosoma mansoni antigen Sm29 in BCG. The approach used here can be used to adjust expression levels for synthetic and/or systems biology studies or for vaccine development to maximize the immune response.

Citing Articles

An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants.

Mambelli F, de Araujo A, Farias J, de Andrade K, Ferreira L, Minoprio P Pathogens. 2025; 14(1).

PMID: 39860984 PMC: 11768231. DOI: 10.3390/pathogens14010023.

Current Understanding of Bacillus Calmette-Guérin-Mediated Trained Immunity and Its Perspectives for Controlling Intracellular Infections.

de Araujo A, Mambelli F, Sanches R, Marinho F, Oliveira S Pathogens. 2023; 12(12).

PMID: 38133271 PMC: 10745672. DOI: 10.3390/pathogens12121386.

Bacterial Spore-Based Delivery System: 20 Years of a Versatile Approach for Innovative Vaccines.

Isticato R Biomolecules. 2023; 13(6).

PMID: 37371527 PMC: 10296236. DOI: 10.3390/biom13060947.

Recombinant Bacillus Calmette-Guérin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge.

Mambelli F, Marinho F, Andrade J, de Araujo A, Abuna R, Fabri V J Immunol. 2023; 210(12):1925-1937.

PMID: 37098890 PMC: 10247535. DOI: 10.4049/jimmunol.2200731.

Engineering a new vaccine platform for heterologous antigen delivery in live-attenuated .

Broset E, Calvet Seral J, Arnal C, Uranga S, Kanno A, Leite L Comput Struct Biotechnol J. 2021; 19:4273-4283.

PMID: 34429847 PMC: 8355830. DOI: 10.1016/j.csbj.2021.07.035.

References

Muller-Taubenberger A, Anderson K . Recent advances using green and red fluorescent protein variants. Appl Microbiol Biotechnol. 2007; 77(1):1-12. DOI: 10.1007/s00253-007-1131-5. View

Davis J, Rubin A, Sauer R . Design, construction and characterization of a set of insulated bacterial promoters. Nucleic Acids Res. 2010; 39(3):1131-41. PMC: 3035448. DOI: 10.1093/nar/gkq810. View

Gall K, Barker L . Differential green fluorescent protein expression from mycobacterial promoter constructs in Escherichia coli and Mycobacterium marinum. FEMS Microbiol Lett. 2006; 255(2):301-7. DOI: 10.1111/j.1574-6968.2005.00078.x. View

Parish T, Stoker N . Electroporation of mycobacteria. Methods Mol Biol. 1999; 101:129-44. DOI: 10.1385/0-89603-471-2:129. View

Ranes M, Rauzier J, Lagranderie M, Gheorghiu M, Gicquel B . Functional analysis of pAL5000, a plasmid from Mycobacterium fortuitum: construction of a "mini" mycobacterium-Escherichia coli shuttle vector. J Bacteriol. 1990; 172(5):2793-7. PMC: 208931. DOI: 10.1128/jb.172.5.2793-2797.1990. View

Zaccolo M, Williams D, Brown D, Gherardi E . An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. J Mol Biol. 1996; 255(4):589-603. DOI: 10.1006/jmbi.1996.0049. View

Varaldo P, Miyaji E, Vilar M, Campos A, Dias W, Armoa G . Mycobacterial codon optimization of the gene encoding the Sm14 antigen of Schistosoma mansoni in recombinant Mycobacterium bovis Bacille Calmette-Guérin enhances protein expression but not protection against cercarial challenge in mice. FEMS Immunol Med Microbiol. 2006; 48(1):132-9. DOI: 10.1111/j.1574-695X.2006.00133.x. View

Taylor R, Walker D, McInnes R . E. coli host strains significantly affect the quality of small scale plasmid DNA preparations used for sequencing. Nucleic Acids Res. 1993; 21(7):1677-8. PMC: 309390. DOI: 10.1093/nar/21.7.1677. View

Ehrt S, Guo X, Hickey C, Ryou M, Monteleone M, Riley L . Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res. 2005; 33(2):e21. PMC: 548372. DOI: 10.1093/nar/gni013. View

10.

Galen J, Levine M . Can a 'flawless' live vector vaccine strain be engineered?. Trends Microbiol. 2001; 9(8):372-6. DOI: 10.1016/s0966-842x(01)02096-0. View

11.

Kremer L, Baulard A, Estaquier J, Poulain-Godefroy O, Locht C . Green fluorescent protein as a new expression marker in mycobacteria. Mol Microbiol. 1995; 17(5):913-22. DOI: 10.1111/j.1365-2958.1995.mmi_17050913.x. View

12.

Alper H, Fischer C, Nevoigt E, Stephanopoulos G . Tuning genetic control through promoter engineering. Proc Natl Acad Sci U S A. 2005; 102(36):12678-83. PMC: 1200280. DOI: 10.1073/pnas.0504604102. View

13.

Cardoso F, Macedo G, Gava E, Kitten G, Mati V, de Melo A . Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis. 2008; 2(10):e308. PMC: 2553283. DOI: 10.1371/journal.pntd.0000308. View

14.

Dhar N, Rao V, Tyagi A . Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis. Med Microbiol Immunol. 2003; 193(1):19-25. DOI: 10.1007/s00430-002-0170-x. View

15.

Luo Y, Szilvasi A, Chen X, DeWolf W, ODonnell M . A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin Diagn Lab Immunol. 1996; 3(6):761-8. PMC: 170444. DOI: 10.1128/cdli.3.6.761-768.1996. View

16.

Dziadek J, Madiraju M, Rutherford S, Atkinson M, Rajagopalan M . Physiological consequences associated with overproduction of Mycobacterium tuberculosis FtsZ in mycobacterial hosts. Microbiology (Reading). 2002; 148(Pt 4):961-971. DOI: 10.1099/00221287-148-4-961. View

17.

Hatfull G, Sarkis G . DNA sequence, structure and gene expression of mycobacteriophage L5: a phage system for mycobacterial genetics. Mol Microbiol. 1993; 7(3):395-405. DOI: 10.1111/j.1365-2958.1993.tb01131.x. View

18.

Triccas J, Britton W, Gicquel B . Isolation of strong expression signals of Mycobacterium tuberculosis. Microbiology (Reading). 2001; 147(Pt 5):1253-1258. DOI: 10.1099/00221287-147-5-1253. View

19.

Varaldo P, Leite L, Dias W, Miyaji E, Torres F, Gebara V . Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect Immun. 2004; 72(6):3336-43. PMC: 415698. DOI: 10.1128/IAI.72.6.3336-3343.2004. View

20.

Nesbit C, Levin M, Hatfull G . Transcriptional regulation of repressor synthesis in mycobacteriophage L5. Mol Microbiol. 1995; 17(6):1045-56. DOI: 10.1111/j.1365-2958.1995.mmi_17061045.x. View